donepezil has been researched along with Postoperative Complications in 7 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair." | 9.15 | Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. ( Appleton, P; Davis, RB; Marcantonio, ER; Palihnich, K, 2011) |
| "This was a pilot, phase 2a study to assess methodological feasibility and the safety and efficacy of donepezil in preventing postoperative delirium after elective total hip replacement surgery in older people without pre-existing dementia." | 9.12 | A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. ( Blanchard, MR; Blizard, R; Bruce, A; Garlick, N; Ndhlovu, PN; Raven, PR; Ritchie, CW; Sampson, EL; Vallance, A; Watts, J, 2007) |
| "This pilot study was unable to demonstrate a benefit for donepezil in preventing or treating delirium in a relatively young and cognitively-intact group of elderly patients undergoing elective orthopedic surgery." | 9.11 | Donepezil in the prevention and treatment of post-surgical delirium. ( Fingeroth, R; Garb, JL; Krushell, R; Laki, A; Liptzin, B, 2005) |
| "A severe intractable delirium caused by the basal forebrain vascular lesion and its dramatic recovery after donepezil administration were reported." | 7.72 | Severe delirium due to basal forebrain vascular lesion and efficacy of donepezil. ( Higashima, M; Kidani, T; Kobayashi, K; Koshino, Y; Mutou, K; Tachibana, O; Yamashita, J, 2004) |
| "To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair." | 5.15 | Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. ( Appleton, P; Davis, RB; Marcantonio, ER; Palihnich, K, 2011) |
| "This was a pilot, phase 2a study to assess methodological feasibility and the safety and efficacy of donepezil in preventing postoperative delirium after elective total hip replacement surgery in older people without pre-existing dementia." | 5.12 | A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. ( Blanchard, MR; Blizard, R; Bruce, A; Garlick, N; Ndhlovu, PN; Raven, PR; Ritchie, CW; Sampson, EL; Vallance, A; Watts, J, 2007) |
| "This pilot study was unable to demonstrate a benefit for donepezil in preventing or treating delirium in a relatively young and cognitively-intact group of elderly patients undergoing elective orthopedic surgery." | 5.11 | Donepezil in the prevention and treatment of post-surgical delirium. ( Fingeroth, R; Garb, JL; Krushell, R; Laki, A; Liptzin, B, 2005) |
| "A severe intractable delirium caused by the basal forebrain vascular lesion and its dramatic recovery after donepezil administration were reported." | 3.72 | Severe delirium due to basal forebrain vascular lesion and efficacy of donepezil. ( Higashima, M; Kidani, T; Kobayashi, K; Koshino, Y; Mutou, K; Tachibana, O; Yamashita, J, 2004) |
| "More donepezil-treated than placebo-treated patients experienced diarrhea, but other adverse effects and safety measures did not differ between groups." | 2.73 | Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial. ( Babyak, MA; Blumenthal, JA; Doraiswamy, PM; Hennig, T; Mathew, JP; Newman, MF; Trivedi, R; White, WD, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seitz, DP | 1 |
| Gill, SS | 1 |
| Gruneir, A | 1 |
| Austin, PC | 1 |
| Anderson, G | 1 |
| Reimer, CL | 1 |
| Rochon, PA | 1 |
| Marcantonio, ER | 1 |
| Palihnich, K | 1 |
| Appleton, P | 1 |
| Davis, RB | 1 |
| Kobayashi, K | 1 |
| Higashima, M | 1 |
| Mutou, K | 1 |
| Kidani, T | 1 |
| Tachibana, O | 1 |
| Yamashita, J | 1 |
| Koshino, Y | 1 |
| Liptzin, B | 1 |
| Laki, A | 1 |
| Garb, JL | 1 |
| Fingeroth, R | 1 |
| Krushell, R | 1 |
| Sampson, EL | 1 |
| Raven, PR | 1 |
| Ndhlovu, PN | 1 |
| Vallance, A | 1 |
| Garlick, N | 1 |
| Watts, J | 1 |
| Blanchard, MR | 1 |
| Bruce, A | 1 |
| Blizard, R | 1 |
| Ritchie, CW | 1 |
| Doraiswamy, PM | 1 |
| Babyak, MA | 1 |
| Hennig, T | 1 |
| Trivedi, R | 1 |
| White, WD | 1 |
| Mathew, JP | 1 |
| Newman, MF | 1 |
| Blumenthal, JA | 1 |
| Wengel, SP | 1 |
| Burke, WJ | 1 |
| Roccaforte, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period[NCT00586196] | Phase 2 | 16 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816] | 40 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Low incidence of delirium.) | |||
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measures severity of 10 delirium symptoms items (0 not present, 1 mild, 2 moderate, 3 severe) yielding a total score of 0 to 30, with 30 most severe. (NCT00586196)
Timeframe: Baseline, hospital discharge, weeks 2, 4 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Change at Hospital Discharge | Change at Week 2 | Change at week 4 | Change at week 6 | |
| Donepezil : 5 mg Each Day for 30 Days | 6.3 | 1.3 | -0.1 | -1.2 | -0.6 |
| Placebo : Encapsulated Cornstarch | 8.4 | 1.6 | -2.2 | -2.0 | -2.0 |
Confusion Assessment Method (CAM)-Measure of the presence or absence of delirium. Requires 1) acute change with fluctuating course, 2) inattention, and either 3) disorganized thinking or 4) altered level of consciousness. (NCT00586196)
Timeframe: Baseline, hospital interviews, weeks 2, 4 and 6
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| basline | hospital interviews | Week 2 | week 4 | week 6 | |
| Donepezil : 5 mg Each Day for 30 Days | 14 | 64 | 43 | 17 | 50 |
| Placebo : Encapsulated Cornstarch | 44 | 64 | 43 | 43 | 50 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | volume percentage (vol%) of red blood ce (Median) |
|---|---|
| Bright Light Therapy | 28.20 |
| Sham Light | 26.70 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | g/dl (Median) |
|---|---|
| Bright Light Therapy | 9.70 |
| Sham Light | 9.55 |
(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | days (Median) |
|---|---|
| Bright Light Therapy | 18 |
| Sham Light | 18.5 |
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Bright Light Therapy | 1 |
| Sham Light | 0 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | thousand cells/uL (Median) |
|---|---|
| Bright Light Therapy | 39 |
| Sham Light | 33.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | M/uL (Median) |
|---|---|
| Bright Light Therapy | 3.21 |
| Sham Light | 2.93 |
"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant
| Intervention | units on a scale (Number) |
|---|---|
| Bright Light Therapy | 18 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | K/uL (Median) |
|---|---|
| Bright Light Therapy | 2.30 |
| Sham Light | 4.75 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mg/dl (Median) | |
|---|---|---|
| Serum Creatinine | Blood Urea Nitrogen (BUN) | |
| Bright Light Therapy | 0.66 | 9 |
| Sham Light | 0.75 | 8.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mmol/L (Median) | |||
|---|---|---|---|---|
| Sodium (Na) | Potassium (K) | Chloride (Cl) | Carbon Dioxide (CO2) | |
| Bright Light Therapy | 139 | 3.6 | 105 | 24.9 |
| Sham Light | 138.0 | 3.80 | 103.0 | 25.10 |
4 trials available for donepezil and Postoperative Complications
| Article | Year |
|---|---|
Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Delirium; Donepezil; Double-Blind Method; Female | 2011 |
Donepezil in the prevention and treatment of post-surgical delirium.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Delirium; Donepezil; Double-Blind Method; Female | 2005 |
A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Delirium; Donepezil; Double-Blind Method; E | 2007 |
Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
Topics: Aged; Cardiopulmonary Bypass; Cognition Disorders; Coronary Artery Bypass; Donepezil; Dose-Response | 2007 |
3 other studies available for donepezil and Postoperative Complications
| Article | Year |
|---|---|
Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.
Topics: Aged; Aged, 80 and over; Anesthesia, General; Cholinesterase Inhibitors; Cohort Studies; Critical Ca | 2011 |
Severe delirium due to basal forebrain vascular lesion and efficacy of donepezil.
Topics: Aged; Basal Ganglia Cerebrovascular Disease; Basal Nucleus of Meynert; Craniopharyngioma; Delirium; | 2004 |
Donepezil for postoperative delirium associated with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Delirium; Donepezil; Geriatric Assessment; Humans; Indans; Male; Nootropic | 1999 |